BATROXIBIN

Benztropine mesylate reduces cholinergic activity to treat Parkinson’s disease and drug-induced EPS. Side effects include confusion, dry mouth, blurred vision, and constipation.

SKU: c4b4eb1dd2a1 Category: Tag:

Product Description


Mechanism of action

Batroxobin is a serine protease derived from *Bothrops atrox* venom. It cleaves fibrinogen at the Aα‑chain to release fibrinopeptide A, producing fibrin monomers that polymerise into weak fibrin clots. Unlike thrombin, batroxobin does not activate factor XIII, yielding clots with altered mechanical properties. It is used to evaluate fibrinogen levels and coagulation dynamics.

Benefits and advantages

Indispensable in haemostasis research, fibrin polymerisation studies, snake‑venom protease characterisation and functional diagnostic assays (e.g., reptilase time). Helps model clot‑formation kinetics independent of thrombin, clarifying contributions of individual coagulation factors.

Side effects and risks

Risks include haemorrhagic imbalance, local irritation, coagulopathy, allergic reactions and systemic toxicity if mishandled. Requires venom‑protein biosafety controls.

Datasheet


Molecular Weight

g/mol

CAS Number

9024-42-4

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

IUPAC/Chemical Name

N/A snake venom serine protease (protein)

References

https://pubchem.ncbi.nlm.nih.gov/#query=9024-42-4;

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download